|
|
The future of effective aerosol therapies
lies in the optimization of drug-to-device and
device-to-drug.
PARI Pharma has taken the
next step and combined
formulation development,
next generation aerosol
platforms, and aerosol characterization under
one roof.
We are currently working with both the eFlow® Technology (lower respiratory) and Vibrent Technology (upper respiratory) Advanced Aerosol delivery platforms.
This multifunctional development program is the
key to creating targeted therapies with high
deposition amounts, low side-effect profiles,
improved patient compliance…and better controlled,
healthier patients.
After 100 years, we know aerosol science
and aerosol delivery.
|
|
|
|
 |
| |
Cystic Fibrosis
PARI’s Altera Delivers Gilead’s Cayston, Approved by European Commission to Treat Cystic Fibrosis [more]
- - - - - - - - - - - - - - - -
Cystic Fibrosis
Mpex Reports Positive Phase II Results with Aeroquin, Delivered by PARI Pharma’s eFlow Technology [more]
- - - - - - - - - - - - - - - -
Cystic Fibrosis
PARI Pharma Reports Successful Phase Ib Clinical Results for Inhaled Liposomal Cyclosporine A and Gains FDA Orphan Drug Designation for the Prevention and Treatment of Bronchiolitis Obliterans [more] |
|
| |
|
